Dexamethasone intratympanic - Otonomy

Drug Profile

Dexamethasone intratympanic - Otonomy

Alternative Names: OTIVIDEX; OTO-104; Sustained release dexamethasone gel - Otonomy

Latest Information Update: 11 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Otonomy
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Meniere's disease
  • Phase II Sensorineural hearing loss

Most Recent Events

  • 22 Jun 2017 Chemical structure information added
  • 04 May 2017 Otonomy completes enrolment in the phase III AVERTS-1 trial for Meniere's disease in USA (Intratympanic)
  • 01 Nov 2016 Phase-II clinical trials in Sensorineural hearing loss (In infants, In children, In adolescents, In adults) in USA (Intratympanic) (NCT02997189)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top